Data Availability Statement
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
References :
1. International Diabetes Federation IDF Diabetes Atlas, 9th edn.
Brussels, Belgium . Atlas la Diabetes la FID (2019).at
<http://www.idf.org/sites/default/files/Atlas-poster-2014_ES.pdf>
2. Neuen, B. L. et al. SGLT2 inhibitors for the prevention of
kidney failure in patients with type 2 diabetes: a systematic review and
meta-analysis. lancet. Diabetes Endocrinol. 7 , 845–854
(2019).
3. Kristensen, S. L. et al. Cardiovascular, mortality, and kidney
outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:
a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol. 7 , 776–785 (2019).
4. Sorensen, C. M. & Holst, J. J. Renoprotective effects of dulaglutide
in patients with T2DM and CKD. Nat. Rev. Nephrol. 14 ,
659–660 (2018).
5. León Jiménez, D., Cherney, D. Z. I., Bjornstad, P., Guerra, L. C. &
Miramontes González, J. P. Antihyperglycemic agents as novel natriuretic
therapies in diabetic kidney disease. Am. J. Physiol. Renal
Physiol. 315 , F1406–F1415 (2018).
6. Jiménez, D. L., Babkowski, M. C. & Miramontes González, J. P. GLP-1
and the renin–angiotensin–aldosterone system. Lancet Diabetes
Endocrinol. 7 , 337 (2019).
7. Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes
in type 2 diabetes (REWIND): a double-blind, randomised
placebo-controlled trial. Lancet 394 , 121–130 (2019).
8. Tuttle, K. R. et al. Dulaglutide versus insulin glargine in
patients with type 2 diabetes and moderate-to-severe chronic kidney
disease (AWARD-7): a multicentre, open-label, randomised trial.Lancet Diabetes Endocrinol. 6 , 605–617 (2018).
9. Boye, K. S. et al. Effects of Dulaglutide and Insulin Glargine
on Estimated Glomerular Filtration Rate in a Real-world Setting.Clin. Ther. 40 , 1396–1407 (2018).
10. Moreno Obregón, F. et al. Real-life experience with
Dulaglutide: Analysis of clinical effectiveness to 24 months.Diabetes Res. Clin. Pract. 158 , 107916 (2019).
11. Levey, A. S. et al. USing standardized serum creatinine
values in the modification of diet in renal disease study equation for
estimating glomerular filtration rate. Ann. Intern. Med.145 , 247–254 (2006).
12. Muskiet, M. H. A. et al. Pleiotropic effects of type 2
diabetes management strategies on renal risk factors. Lancet
Diabetes Endocrinol. 3 , 367–381 (2015).
13. Rossing, K. et al. Progression of nephropathy in type 2
diabetic patients. Kidney Int. 66 , 1596–1605 (2004).